Gilead Sciences (GILD)
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
$174.48+4.19%
Close 2026-11-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
Research Workspace
Put GILD beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Product sales excluding Veklury reach $29.4B to $29.8B: Direct metric needs a verified mapping.
View ThesisRevenue is growing steadily — about 7% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 18%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskGilead's product sales excluding Veklury must keep compounding to justify the price. Revenue growth is slowing, dropping from 10% to 7% year over year. The latest quarter beat expectations by 17.5%. The stock trades at 6.8 times sales. Peers trade at 8.9 times sales. The price reflects less growth than we forecast. The primary pillar is under pressure. Product sales excluding Veklury need a verified mapping. The thesis comparison is not yet verified. Peer multiples imply a price about 19% above where it trades. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-04. GILD is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 28 analysts currently covering GILD (as of Nov 2026).
Based on 12 Wall Street analysts offering 12-month price targets for GILD in the last 4 months.
Continue this research
Compare GILD with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| GILD Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 4 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put GILD next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Advance lenacapavir and HIV prevention
Direct competitor approval threatens lenacapavir market exclusivity.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $174.48
The last 12 months of price, then the range of analyst 12-month targets from today’s $174.48.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Grow product sales excluding Veklury
Official Q3 earnings confirm strong product sales growth.
Advances: Increase product sales excluding Veklury
Raised 2026 sales outlook supports ex-Veklury growth; 2028 Biktarvy price cuts are a future headwind.
Advances: Expand oncology and inflammation through pipeline and acquisitions
Jefferies raises target citing acquisition, validating oncology expansion strategy.
Advances: Expand oncology and inflammation through pipeline and acquisitions
Named oncology trial collaboration broadens development activity but remains early.
Advances: Expand oncology and inflammation through pipeline and acquisitions
Positive mid-stage trial data supports oncology/inflammation pipeline expansion.
Advances: Advance lenacapavir for HIV prevention
India's eased approval pathway supports potential access for long-acting HIV prevention.
Advances: Advance lenacapavir and HIV prevention
Licensing deal expands lenacapavir reach, advancing HIV prevention objective.